Q-omics provides the consensus-scored GYS2 profile across patient tissues and cancer cell-line models. GYS2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GYS2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, GYS2 RNA expression shows 17,190 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where GYS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GYS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GYS2 survival associations across molecular data types. GYS2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GYS2 RNA expression–survival associations across cancer types. High GYS2 expression shows unfavorable associations in UVM and MESO, but favorable associations in BLCA, LIHC, SKCM and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GYS2 RNA expression.
This table summarizes GYS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GYS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GYS2 shows lower tumor expression in HNSC, THCA, LIHC, BRCA and CHOL and higher tumor expression in KIRP. The HNSC box plot shows higher GYS2 RNA expression in normal versus tumor tissue (log2 FC = −1.359, t-test p < 0.001).
This table shows molecular features associated with GYS2 in patient tissues and cancer cell lines. In patient samples, GYS2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GYS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
